NEMLUVIO is the first authorized monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling ...

A drug approved to treat eczema provided significant improvement in the symptoms of patients with severe itching diseases that currently have no targeted treatments, according to a new study. The drug ...

Advancements in the form of recent approvals and an evolving pipeline landscape in dermatology will bolster Leo’s chance of ...

The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.

Total yearly flares in atopic dermatitis correlate with disease severity and impaired quality of life, influencing treatment decisions. Higher flare frequency is associated with increased disease ...

Seborrheic dermatitis is positively associated with a range of epithelial barrier diseases, including dermatologic, respiratory, gastrointestinal, and ocular diseases.

Seborrheic dermatitis may disrupt the skin barrier, potentially exposing patients to other epithelial barrier diseases (EBDs) across various organ systems. A large cohort study found positive ...

A global study finds that almost half of all people with conditions like atopic dermatitis, psoriasis, and acne are unable to sleep well at night, which can leave them struggling to perform well at ...